NCT02395263Unknown2 期
Proof Of Concept Study of Yuxintine in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 160
- 试验地点
- 10
- 主要终点
- The change of total score from baseline in MADRS scale
研究概览
简要总结
The purpose of this study is to determine whether Yuxintine Capsule in different doses are effective in the treatment of Depression.
And to explore the preliminary information of safety and efficacy of Yuxintine Capsule in the Chinese Patients with Depression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult with primary diagnosis of major depressive disorder(MDD) based on the criteria of DSM-IV-TR, single episode or recurrent episode, not accompanied with psychotic symptoms. Coding of diagnosis included: 296.2 and 296.
- •The Subject with Heart-Spleen Deficiency based on the CTM.
- •The total score of MADRS is ≥22 in both screening visit and baseline visit.
- •The total score of HAMD-17 is ≥18 and ≤30, AND item 1 ≥2 in both screening visit and baseline visit.
- •The subject understands and consents to takes part in this clinical trials. The subjects should sign informed consent.
排除标准
- •The subject made a suicide attempt in recent 6 months or has a score ≥3 on item 3(suicide assessment) of the HAMD.
- •The subject has a current DSM-Ⅳ-TR axisⅠpsychiatric diagnosis other than depression.
- •When the MADRS score of baseline visit compares with the screening visit, the decreasing rate is ≥25%.
- •Any unstable cardiovascular, hepatic, renal, endocrine(thyroid gland dysfunction), blood(e.g. bleeding tendency),or other medical disease.
- •Had a history of seizure disorder,except infantile febrile convulsion.
- •The subject has accepted psychosurgery or electroconvulsive therapy within 3 months.
- •With psychotic symptoms.
- •The subject has a history of mania episode, including manic, mixed or rapid cycle attack.
- •The subject has a current diagnosis or history of depression due to any other psychotic disorder or a general medical condition.
- •The subject with refractory depressive disorder,i.e.the patients who used at least two different mechanisms antidepressants with adequate dosage and duration treatment still had no respond.
- •Clinically significant electrocardiographic(ECG) abnormalities or abnormal laboratory values(eg. Hepatic function above 1.5 times of clinical toplimit, renal function index above toplimit, abnormal coagulation function and clinical significance of abnormality, i.e. Prothrombin time shorten or extend more than 3 seconds or a dynamic variation or APTT prolonged more than 10 seconds,AND fibrinogen L or been progressive decline, or > 4.0 g/L).
- •The subject has a diagnosis of alcohol or other substance abuse or dependence at least 1 years prior to the baseline visit.
- •Known hypersensitivity to Ginseng, or at least to two kinds of drugs, or serious allergic physique.
- •Women who were pregnant, breast-feeding, or planning to become pregnant during study. Men who have request to fertility during study period. The subject could not take safe and effective birth control measures.
- •The subject could not take medication according to the doctor's advice.
- •The subject uses antidepressant drug normally before 2 weeks of screening, and stops using psychotropic drug less than 7 half-life period (monoamine oxidase inhibitor more than 2 weeks).
- •The subject has participated in a drug clinical trial within 3 months before screening.
- •The investigator think the subject is unsuitable to enrol in this clinical trial.
研究组 & 干预措施
Yuxintine 200mg per day
Experimental
Yuxintine 200mg oral, once a day, 6 weeks
干预措施: Yuxintine (Drug)
Yuxintine 300mg per day
Experimental
Yuxintine 300mg oral, once a day, 6 weeks
干预措施: Yuxintine (Drug)
Yuxintine 400mg per day
Experimental
Yuxintine 400mg oral, once a day, 6 weeks
干预措施: Yuxintine (Drug)
Placebo
Placebo Comparator
Placebo oral, once a day, 6 weeks
干预措施: Yuxintine (Drug)
结局指标
主要结局
The change of total score from baseline in MADRS scale
时间窗: 6 weeks
次要结局
- clinical remission rate according to MADRS(6 weeks)
- CGI(CGI-S,CGI-I)(6 weeks)
- The change of total score from baseline in HAMD scale(6 weeks)
- decreasing rate from baseline in HAMD scale(6 weeks)
- clinical remission rate according to HAMD(6 weeks)
- change from baseline in HAMA(6 weeks)
- Traditional Chinese Medicine Syndrome Scale(6 weeks)
- clinical response rate according to MADRS(6 weeks)
研究者
研究点 (10)
Loading locations...
相似试验
Unknown
不适用
A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth DiseaseHand, Foot and Mouth DiseaseNCT01182025The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine360
尚未招募
早期 1 期
Clinical Efficacy and Mechanism of Yisui Granule in Treatment of Low and Medium Risk Myelodysplastic Syndrome Through DemethylationMDSNCT05687513Dongzhimen Hospital, Beijing76
招募中
2 期
Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes PatientsType2diabetesDiabetesDiabetes Mellitus, Type 2NCT06575478Beijing Supreme Life Pharmaceutical Technology Co., Ltd.72
已完成
4 期
Effectiveness and Safety of Yiqitongluo Granule for StrokeStrokeNCT02604654Yi Yang2,197
已完成
2 期
Comparison of Anyu Peibo With Placebo in Treatment of MDDMajor Depressive Disorder (MDD)NCT02380066Shanghai Mental Health Center120